Medication info
Hudiang Duo Sustained Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Hudiang Duo Sustained Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Pale pink double convex oval sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501552 · Approved 2025.06.23 · Insurance code 670609540

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. Take one tablet of this drug 10/1000 mg extended-release or 25/1000 mg extended-release once daily. Patients taking this drug 5/1000 mg extended-release or 12.5/1000 mg extended-release should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the feces. It is not known whether the substance excreted in the feces contains the active ingredient of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). Special populations Renal impairment Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. Older adults In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes

  • Type 2 diabetes
  • blood sugar irregularities
  • cardiovascular diseases
View approved original text

This medication is used in conjunction with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes. It is particularly effective for patients whose blood sugar is not adequately controlled and requires caution when used in patients with cardiovascular diseases. Information from clinical trials by experts can confirm safety regarding the occurrence of cardiovascular events. Therefore, this medication aids in controlling blood sugar and managing cardiovascular-related risks in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. Take one tablet of this drug 10/1000 mg extended-release or 25/1000 mg extended-release once daily. Patients taking this drug 5/1000 mg extended-release or 12.5/1000 mg extended-release should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the feces. It is not known whether the substance excreted in the feces contains the active ingredient of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). Special populations Renal impairment Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. Older adults In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Precautions

This medication is primarily used for the treatment of diabetes, where the two components work together to control blood sugar. When taking this medication, it is essential to verify that kidney function is normal and should not be administered to patients with severely impaired kidney function. It should be used with caution in cases of severe infections, dehydration, acute heart problems, or severe liver function impairments, as this can pose risks. Women who are pregnant or may become pregnant should avoid taking this medication, and it is also advisable to refrain from use during breastfeeding. This medication may cause lactic acidosis, a rare but serious side effect, which is a condition where lactic acid accumulates excessively in the body and requires immediate treatment. Additionally, this medication can induce hypoglycemia, so careful monitoring of blood sugar levels is necessary when taken with insulin or other blood sugar-lowering agents. Urinary and genital infections may occur, so if symptoms of infection appear, consult a physician immediately. Prior to and following surgeries or examinations using iodinated contrast agents, the use of this medication should be temporarily halted and recommenced only after kidney function has returned to normal. This medication may lead to fluid volume reduction, so special care is needed in cases of dehydration or among older adults or patients with low blood pressure. During use, Vitamin B12 levels may decrease, so regular testing is recommended. While taking this medication, report any sudden muscle pain, difficulty breathing, or severe fatigue to healthcare personnel immediately. Do not crush or chew the tablet; swallow it whole, and it may appear in the stool, which is normal.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • perineal necrosis
  • vitamin B12 reduction and deficiency
  • ketoacidosis
  • fluid volume reduction
Show 155 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disorder
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • increased urination
  • urinary difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated blood creatinine
  • decreased glomerular filtration rate
  • nausea
  • malaise
  • gastric ulcer
  • colitis
  • ischemic colitis
  • gastrointestinal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorder
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • orthostatic dizziness
  • sensory loss
  • drowsiness
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual sputum
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • ligament injury
  • ligament sprain
  • arthralgia
  • lower back pain
  • musculoskeletal pain
  • bone loss
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • cough
  • dyspnea
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • diabetic foot
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • diabetic retinopathy
  • dry eyes
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • rib fracture
  • iliotibial band syndrome
  • angina pectoris
  • unstable angina
  • hypertension
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent exposure to air or moisture. It is recommended to keep it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale pink double convex oval sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.